Scott Benner Scott Benner

The Other Pandemic: Why the WHO is Sounding the Alarm on a Global Crisis

According to the World Health Organization (WHO), we are no longer just "gaining weight"—we are in the midst of a structural health collapse that affects 1 in 8 people on the planet.

The WHO’s latest fact sheet on obesity isn't just a collection of numbers; it is a red alert. Here is what the data says, why it matters, and the aggressive "Acceleration Plan" the world is launching to fight back by 2030.

The Numbers: A Doubling of the Disease

If you feel like obesity is more common now than when you were a child, you aren't imagining it. The WHO data reveals a staggering generational shift:

  • Adults: Since 1990, worldwide adult obesity has more than doubled. As of 2022, over 890 million adults are living with obesity.

  • Children & Adolescents: The statistics here are even more alarming. Adolescent obesity has quadrupled since 1990. Today, over 390 million young people (aged 5–19) are overweight, setting them up for a lifetime of chronic health battles.

  • The "Double Burden": Perhaps the most tragic finding is that obesity is no longer just a "rich country" problem. Low- and middle-income countries are now facing a "double burden"—struggling with undernutrition and infectious diseases while simultaneously facing a rapid rise in obesity due to cheap, processed foods.

The Cause: It’s Not Willpower, It’s the Environment

For decades, the narrative around weight was simple: "Eat less, move more." The WHO explicitly rejects this outdated view.

The fact sheet defines obesity as a chronic, complex disease driven by "obesogenic environments." It’s not that people suddenly lost their willpower in 1990; it’s that our world changed. Global shifts in food systems have made energy-dense, nutrient-poor foods the cheapest and most accessible options. When you combine this with sedentary work and urban planning that discourages movement, you create a perfect storm that biology cannot easily fight.

The Future: The 2030 Acceleration Plan

So, what is the plan? Recognizing that we are off track, the World Health Assembly endorsed the "Acceleration Plan to STOP Obesity." This is the roadmap for the next five years, and it shifts the focus from individual dieting to systemic policy change.

The Goal: The immediate target is to halt the rise of diabetes and obesity by 2030.

The Strategy: The WHO is pushing member states to implement "Best Buys"—policies that are proven to work but often face industry resistance:

  1. Sugar Taxes: Fiscal policies to make sugary drinks and unhealthy foods more expensive.

  2. Marketing Restrictions: Banning the advertising of high-fat, high-sugar foods to children.

  3. Front-of-Pack Labeling: Clear warning labels that cut through marketing buzzwords.

  4. Primary Care Integration: Moving obesity treatment out of expensive specialty clinics and into standard primary care.

The Economic Ticking Clock

If health arguments don't move policymakers, money will. The economic forecast is grim: if current trends continue, the global cost of overweight and obesity is predicted to reach $3 trillion per year by 2030 and a staggering $18 trillion by 2060. This includes healthcare costs and lost productivity, a bill that could cripple developing economies.

Where Do Pills Fit In?

Interestingly, the WHO released new guidelines in December 2025 regarding GLP-1 therapies (like Wegovy). Their stance? Cautious optimism. They recognize these drugs are powerful tools for treatment, but they warn that they are not a silver bullet for prevention.

We cannot medicate our way out of a bad food system. The future of global health depends on a two-pronged approach: using advanced therapies for those who are already sick, while aggressively changing the laws and environments to stop the next generation from getting sick in the first place.

Sources and Further Reading

Read More
Scott Benner Scott Benner

The Wegovy Pill Arrives and Ignites the Next Phase of the Obesity Treatment Wars

For the past few years, the cultural conversation around obesity has been dominated by a weekly ritual: the injection. Drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have fundamentally shifted how we treat chronic weight management, offering efficacy previously only seen with bariatric surgery. But for millions of people, the barrier of a weekly needle—no matter how small—remained significant.

That barrier just crumbled.

In a watershed moment for metabolic medicine, the FDA has approved Novo Nordisk’s Wegovy® pill, the first-ever high-dose oral GLP-1 specifically for weight loss in adults. This isn't just a new delivery method; it's the opening salvo in a fierce, forward-looking battle between pharma giants Novo Nordisk and Eli Lilly to define the future of metabolic health.

Here is a look at the new pill, and why it’s just the beginning of an intense innovation race over the next few years.

The Wegovy Pill: Matching the Shot without the Sting

The holy grail of GLP-1 research has long been creating a pill that works as well as the injections. The stomach is a hostile environment for complex biological drugs like semaglutide (the active ingredient in Wegovy and Ozempic), making oral delivery notoriously difficult.

According to the data supporting its approval, Novo Nordisk has cracked the code.

The FDA approval was based on the pivotal OASIS 4 phase 3 trial. The results showed that the once-daily Wegovy pill is not a watered-down version of its injectable counterpart. It is a powerhouse on its own.

  • The Data: In the trial, adults taking the Wegovy pill achieved an average weight loss of approximately 14%regardless of adherence. For those who stayed on the treatment consistently, the average loss was nearly 17% over 64 weeks.

  • The Comparison: These numbers are strikingly similar to the results seen in the original clinical trials for the weekly Wegovy injection.

  • The Timeline: Novo Nordisk has moved quickly, with the pill launching in the US in early January 2026.

For patients, this means the choice between an injection and a pill is no longer about sacrificing efficacy for convenience. They are now functionally equivalent options.

The Future Outlook: The Arms Race Heats Up

While the Wegovy pill is a massive victory for Novo Nordisk today, the landscape of 2026 and beyond is advancing rapidly. Both Novo Nordisk and its main rival, Eli Lilly, are deep into late-stage testing of next-generation therapies designed to be even more potent or easier to take.

The goal for both companies is clear: move beyond just GLP-1 and target multiple hormone receptors simultaneously to supercharge metabolism and improve glucose control.

Novo Nordisk’s Next Moves: Doubling Down

Novo Nordisk is seeking to defend its lead by maximizing the potential of semaglutide and introducing powerful combination therapies.

1. High-Dose Oral Semaglutide for Diabetes (Trial Phase: Late Stage) While the new Wegovy pill is for obesity, Novo is actively testing these higher oral doses for type 2 diabetes. Current oral semaglutide for diabetes (Rybelsus) is effective but lower dose. The success of the Wegovy pill suggests a high-dose diabetes pill is likely on the near-term horizon, offering diabetes patients unprecedented oral blood sugar control and weight loss benefits.

2. CagriSema: The Combination Punch (Trial Phase: Phase 3) The most anticipated drug in Novo’s immediate pipeline is CagriSema. This is a weekly injection that combines semaglutide with a new drug called cagrilintide (an amylin analogue).

  • The Goal: Early data suggests CagriSema could offer even greater weight loss than current Wegovy injections, potentially exceeding the 20% threshold, and may offer a faster onset of action.

  • Timeline: Crucial Phase 3 data is expected soon, positioning it as the potential successor to the current injectable throne.

Eli Lilly’s Counterattack: Convenience and Power

Eli Lilly, riding high on the success of tirzepatide (Mounjaro/Zepbound), has perhaps the most diverse and aggressive pipeline in the industry. They are attacking on two fronts: ultimate convenience and ultimate power.

1. Orforglipron: The "Easy" Pill (Trial Phase: Phase 3) This is perhaps the biggest threat to Novo's new oral dominance. The current oral semaglutide technology has a catch: it must be taken on an empty stomach with no food or drink for 30 minutes afterward, or it doesn't work well.

  • The Goal: Lilly’s orforglipron is a different type of molecule ("small molecule") designed to be taken daily withoutstrict food or water restrictions. If successful in its ongoing Phase 3 trials, it could become the preferred oral option due to ease of use.

  • Timeline: Lilly has signaled plans to submit this for approval potentially in 2026.

2. Retatrutide: The "Triple G" Heavyweight (Trial Phase: Phase 3) If current drugs are double-receptors, Retatrutide is the triple threat. It targets GLP-1, GIP, and glucagon receptors.

  • The Goal: Phase 2 data was astonishing, showing weight loss approaching an average of 24%. This level of efficacy is beginning to rival the very best outcomes of invasive bariatric surgery. It is also showing profound effects on liver fat.

  • Timeline: Massive Phase 3 trials are underway, with results eagerly anticipated in the next couple of years.

A New Era of Options

The approval of the oral Wegovy pill is a celebratory moment for patient access. It democratizes a powerful therapy that was previously restricted to those willing to inject.

However, in the grand scheme of metabolic medicine, today is just the starting gun for the next lap. With Novo Nordisk pushing combination therapies and Lilly aiming for unrestricted pills and triple-agonist powerhouses, patients with obesity and diabetes will soon have an arsenal of highly customized tools to manage their chronic conditions.

Sources and Further Reading

Read More
Scott Benner Scott Benner

Nationwide Omnipod Recycling Program

Hello Friends!

The Omnipod Recycling Program is Going Nationwide! ♻️🌍

I have some absolutely fantastic news to share with you all today. If you’ve been listening to the podcast or following the T1D tech world for a while, you know that one of the biggest questions we always ask is: "But what do we do with all the plastic?"

Well, Insulet has heard us loud and clear. 🎉

As of today, the Omnipod Recycling Program has officially expanded nationwide across the U.S.! This is a huge step forward for our community and for the planet. We are talking about diverting millions of Pods from landfills and turning them into something new.

Why This is a Big Deal ✨

We all love the freedom of tubeless pumping, but looking at that pile of used Pods can sometimes feel a little heavy on the conscience. This expansion means that whether you are in Miami, Seattle, or anywhere in between, you now have a direct, free way to dispose of your Pods responsibly.

Insulet isn’t just tossing them in a different bin, either. They are partnering with specialized recyclers to decontaminate the Pods and reclaim the materials (like batteries and metals) to be reused. It’s a massive win for sustainability in the diabetes space.

How It Works (It’s Super Simple!) 👇

They have made the process incredibly easy for us. Here is the lowdown:

  1. Request a Kit: Head over to the Omnipod website and request your free recycling kit.

  2. Fill It Up: The kit comes with a prepaid shipping label and a box that holds up to 60 Pods. That is roughly 6 months of supplies!

  3. Send It Back: Once your box is full, just seal it up and drop it off at FedEx or USPS. That’s it!

Let’s Do This Together 🤝

I am so excited to see a major player like Insulet taking responsibility and giving us the tools to be more eco-friendly. It’s one less thing to worry about and one more way we can take care of the world while we take care of ourselves.

So, go grab your kit, tell your dia-buddies, and let’s start filling those boxes!

Check out the full details and grab your kit here: https://www.omnipod.com/pod-recycling-pilot

Read More
Scott Benner Scott Benner

Why Your Carb Ratio Stopped Working (And Why It’s Not Your Fault)

You count the carbs perfectly. You weigh the food. You punch the numbers into your pump or calculate the dose for your pen exactly as your doctor taught you. The math is perfect.

And then, 45 minutes later, you watch your Dexcom arrow shoot straight up. You hit 250 mg/dL. You stay there for two hours, frustrated and exhausted, before crashing back down.

You assume the problem is the math. You think, "My insulin-to-carb ratio must be wrong. I need more insulin."

Here is the trap: If you change your ratio, you will likely go low next time. The problem isn't the amount of insulin. It’s the timing.

The "Right Amount" at the "Wrong Time" is Still a High

Standard medical advice teaches us to "Bolus and Eat." But this advice ignores the laws of physics.

  • The Reality: Standard rapid-acting insulin takes 15–20 minutes to begin working and 60–90 minutes to peak.

  • The Problem: Modern processed food (even "healthy" carbs) hits your bloodstream in minutes.

If you bolus and eat immediately, the food wins the race. It spikes your blood sugar before the insulin even wakes up. By the time the insulin starts working, it’s too late—you are already chasing a high.

The Solution: The "Tug-of-War"

Imagine your blood sugar is a flag in the middle of a tug-of-war rope. On one side is Insulin (pulling down). On the other side are Carbs (pulling up).

If you let the Carbs start pulling 20 minutes before the Insulin shows up, the flag flies into the sky (a spike).

To win, you must give the insulin a "head start." This is called a Pre-Bolus. By dosing 15, 20, or even 30 minutes before you eat, you allow the insulin to start pulling down just as the food starts pulling up. The forces cancel each other out, and the flag (your blood sugar) stays in the middle.

⚠️ The Safety Check (Read Before You Bolus)

Pre-bolusing is a power tool, but you must respect the current data. Context is King.

  1. Never Pre-Bolus a Low: If your blood sugar is low (e.g., under 70 mg/dL) or your arrow is trending down, do not wait. Eat immediately. The "Tug-of-War" is already lost; you need the carbs to pull up instantly.

  2. The "Pizza Effect": High-fat/high-protein meals digest much slower than standard carbs. If you pre-bolus a heavy meal (like pizza or steak) by 20 minutes, you may crash before the food digests. These meals often require an extended bolus or different timing.

  3. Know Your Insulin: If you use ultra-rapid insulin (like Fiasp or Lyumjev), your wait times will be much shorter.

Stop Chasing the Ghost

You don’t need to change your ratio yet. You need to change your timing. You need to understand that "Timing and Amount" are equal partners. Even the perfect amount of insulin will fail if it arrives late to the party.

Ready to stop the spikes?

You don’t have to live on a rollercoaster. We break down exactly how to time your insulin safely, how to handle high-fat foods, and how to test your Pre-Bolus timing in the Diabetes Pro Tip Series.

Start Here:

🎧 Episode 1003: Pre-Bolus (The strategy that changes everything) - Apple Device, Spotify

🎧 Episode 1002: All About Insulin (Understanding how your tool actually works) - Apple Device, Spotify

🎧 Episode 1428: Small Sips Tug of War (The visual that makes it click) - Apple Device, Spotify

Stop blaming yourself for "bad numbers." It’s just data. And now you have the data to fix it.

Read More
Scott Benner Scott Benner

How Hypothyroidism Alters Life with Type 1 Diabetes

Type 1 Diabetes × Hypothyroidism: what really changes (and how to manage it)

Why these two travel together

Both T1D and autoimmune thyroid disease are common autoimmune partners. Meta-analyses and reviews consistently show higher thyroid autoimmunity and thyroid dysfunction in people with T1D than in the general population—often antibody-positive first, with a subset progressing to overt hypo- or hyperthyroidism. Routine thyroid screening is recommended in standards of care for people with T1D. American Diabetes Association+3OUP Academic+3Frontiers+3

How hypothyroidism alters glucose control (two competing effects)

1) The “more resistant” pattern (often daytime) — supported, but variable

Low thyroid hormone can increase peripheral insulin resistance, particularly in muscle and adipose tissue. Clinically this can look like higher basal needs and post-meal spikes despite familiar carbs. Several human studies and reviews—especially in subclinical hypothyroidism—report worsened insulin resistance indices. Magnitude varies, and results aren’t uniform across all populations. OUP Academic+3BMJ Open+3BioMed Central+3

2) The “more sensitive (and lower dose)” pattern (often overnight/fasted) — supported in T1D case series/reviews

In T1D, untreated hypothyroidism can also reduce insulin clearance and slow gastric emptying, raising the risk of unpredictable hypoglycemia and lower insulin requirements (sometimes markedly) until euthyroid. This is described in ADA-family journals and case series; in practice it shows up as frequent lows and a need to step basal/bolus down while thyroid therapy is optimized. Diabetes Journals

What this means in the real world: some people with T1D + hypothyroidism see higher doses and more spikes; others see lower doses and more lows; many cycle between both as meals, activity, and gastric timing change. Expect pattern volatility until thyroid levels stabilize. (Mechanistic synthesis from sources above.)

Day-to-day signals that your thyroid may be off

  • Your settings stop making sense: post-meal spikes despite careful counting or a run of unexplained lows—especially with fatigue, cold intolerance, dry skin/hair, or weight change.

  • Basal “creep” or sudden drop: rising basals over weeks or the opposite—needing 10–30% less insulin with more lows, particularly overnight. Diabetes Journals

  • Carpal tunnel/neuropathy, cramps, stiffness grow as glucose variability worsens. (Common with hypothyroid; can complicate device use and manual dexterity.) Diabetes Journals

Screening & monitoring (what guidelines say)

  • Screen at diagnosis and repeat periodically: ADA Standards call out the increased autoimmune burden in T1D and endorse ongoing screening for thyroid disease (TSH ± free T4; antibodies when indicated). Pediatric and primary-care abridged resources and update decks explicitly note initial and repeat thyroid screening at regular intervals for T1D. Frequency is individualized (e.g., annually or if symptomatic/antibodies positive/pregnancy planning). Diabetes Journals+2Diabetes Journals+2

  • Kids/teens with T1D: pediatric standards and ISPAD materials reinforce periodic thyroid checks given higher autoimmune clustering in youth. ISPAD+1

Suspected (needs more precision): exact “best” interval (e.g., every 1 vs 2 years) isn’t identical across guidelines and often depends on antibodies, symptoms, and prior results. (Guideline synthesis.) Diabetes Journals

Adjusting insulin and tech while hypothyroid is treated

  1. Expect a moving target for 6–8 weeks after any levothyroxine change—the time it takes for TSH to re-equilibrate. Re-review basals, ISF, and I:C after each thyroid dose change or major lab shift. Diabetes Journals

  2. If lows predominate (esp. fasting/overnight), first cut basal 10–20% and watch CGM overnight trends; consider more conservative correction factors until euthyroid. Diabetes Journals

  3. If spikes dominate (esp. post-meal), review I:C and pre-bolus timing; consider modest basal increases only if nocturnal/fasting is also drifting up. (Balances the resistance vs clearance effects described above.) BMJ Open

  4. Closed-loop/automation: expect algorithm “thrash” (over-correction, then suspends). Tighter alerts and shorter insulin-on-board assumptions can help during thyroid dose titration. (Practice inference based on mechanisms above.)

Suspected: we don’t have RCT-level data tying specific percentage changes in pump settings to degrees of hypothyroidism—the adjustments above are principle-driven and should be individualized. OUP Academic

Lipids, heart, kidneys: double-checking the “silent risks” in T1D

  • Hypothyroidism worsens LDL/TG and can add bradycardia/low output—stacking CV risk on top of T1D. Treating the thyroid state typically improves lipids; re-check the lipid panel after euthyroid is achieved before escalating statin therapy. Diabetes Journals

  • Overt hypothyroidism can lower eGFR and raise creatinine; kidney measures often improve after thyroid replacement—helpful context when interpreting microalbumin trends in T1D.

Suspected: CV event reduction with treating subclinical hypothyroidism is debated and likely age/TSH-dependent. Paloma Health

Pregnancy planning with T1D: thyroid gets a front-row seat

Untreated or undertreated maternal hypothyroidism increases risks (miscarriage, pre-eclampsia, low birth weight, neurodevelopmental effects). In T1D—where pregnancy is already high-touch—dose adjustments and tighter thyroid targets are standard; check early and often, including pre-conception. OUP Academic

Suspected: universal treatment thresholds for subclinical hypothyroidism in pregnancy still vary by guideline (TSH cutoffs, antibody status). Discuss individualized targets. Paloma Health

Quick checklist for people with T1D

  • Ask for labs when your settings go sideways: TSH + free T4 (and TPO antibodies if not known). Diabetes Journals

  • Stay consistent with levothyroxine (empty stomach, same time daily; separate from iron/calcium/PPIs). Re-test 6–8 weeks after any change. Diabetes Journals

  • Expect insulin changes during thyroid titration—log basal/bolus moves and CGM patterns; adjust gradually. Diabetes Journals

  • Re-check lipids and kidney labs once euthyroid before making big therapy jumps. Diabetes Journals

  • If pregnant/trying: loop in endocrine + OB early; monitor thyroid more frequently than usual. OUP Academic

Bottom line for T1D

Hypothyroidism changes the rules of insulin math through two opposite forces—a tendency toward peripheral resistance and a tendency toward lower insulin clearance and delayed gastric emptying. Which one dominates differs by person and even time-of-day. Screen regularly, treat to euthyroid, and expect to adjust insulin settings more than once on the way there. Once the thyroid is steady, your CGM and pump behave more predictably again. BMJ Open+1

Read more about the type 1 diabetes impacts.

🎧 Hear an Endocrinologist Break It Down

If you want to hear this topic straight from a specialist who lives it every day, listen to Episode 413 of the Juicebox Podcast featuring Dr. Adi Benito, an endocrinologist who explains how thyroid disorders and Type 1 diabetes constantly influence each other.

In this conversation, Dr. Benito and Scott unpack:

  • Why thyroid problems are so common in people with Type 1 diabetes

  • How low thyroid levels quietly distort insulin sensitivity, digestion, and weight

  • What “normal” thyroid labs can miss — and when to push for deeper testing

  • How treating hypothyroidism can smooth out blood-sugar swings and energy levels

It’s a practical, myth-busting talk that connects the science to real-world management — exactly the kind of clarity you wish every endo visit had.

👉 Listen to Juicebox Podcast Episode 413 — Dr. Adi Benito on Thyroid and Type 1 Diabetes

🔬 Understanding Your Thyroid Test Results — The Real-World Breakdown

1. “Normal” vs. “Optimal”

  • Reference range for TSH: ~0.45 – 4.5 mIU/L

  • Optimal range for most people: ~0.5 – 2.5 mIU/L
    A “normal” result doesn’t always mean your thyroid is working optimally for you. Many people still experience fatigue, weight gain, brain fog, or glucose swings even when their numbers look fine.

2. Why “In-Range” Doesn’t Always Mean Healthy

TSH is a pituitary signal, not a direct measure of thyroid hormone activity in your cells. You can have “normal” TSH and still feel hypothyroid because of issues downstream—like how your body converts, absorbs, or uses those hormones.

You can have normal labs and still struggle with:

  • Poor conversion of T4 → T3 (the active hormone)

  • Iron, selenium, or B12 deficiency affecting hormone use

  • Autoimmune gastritis or celiac disease blocking absorption

  • Early Hashimoto’s, where antibodies are active but the gland isn’t fully failing yet

3. When to Treat

Treatment decisions aren’t just about numbers—they’re about patterns, context, and how you actually feel.

Guideline-based starting points:

  • TSH > 6–7 mIU/L (especially under age 65): raises cardiovascular and stroke risk → treat.

  • TSH > 2.5 mIU/L in women trying to conceive or pregnant → treat.

  • Goiter + positive antibodies → treat, even if TSH is still “normal.”

Symptom-driven care:

  • If symptoms of hypothyroidism persist—fatigue, brain fog, cold intolerance, slow recovery from lows, brittle hair, joint pain—you still deserve investigation.

  • In select cases, clinicians may trial low-dose therapy or adjust medication based on symptoms, even with “borderline” or “normal” labs, after ruling out other causes.

  • The goal: treat the person, not the paper. Labs confirm the story; they shouldn’t silence it.

4. Beyond TSH: Tests That Tell the Full Story

Ask for a more complete panel when something feels off:

  • Free T4 and Free T3 — show active hormone levels

  • Thyroid peroxidase (TPO) and thyroglobulin antibodies (TgAb) — detect Hashimoto’s

  • Ferritin and vitamin B12 — deficiencies mimic hypothyroid fatigue

  • Vitamin D — supports immune and thyroid function

  • Reverse T3 (if symptoms persist) — shows blocked hormone conversion

5. Symptoms That Should Prompt a Re-Check

  • Fatigue, sluggishness, or mental fog

  • Feeling cold easily

  • Weight changes without reason

  • Joint or muscle pain

  • Hair loss, dry skin, or brittle nails

  • Constipation

  • Irregular or heavy periods

  • Repeated low blood sugars or insulin resistance swings

  • In kids: slowed growth or delayed puberty

6. Frequency of Monitoring

  • Every 6–12 months if stable

  • Every 6–8 weeks after a dose change or when symptoms return

  • More often if pregnant, switching meds, or changing insulin regimens (for people with T1D)

7. Medication Realities

  • Consistency is everything: stay with the same brand/manufacturer—shape and color matter.

  • Take on an empty stomach, 30–60 minutes before breakfast; avoid coffee, calcium, iron, and magnesium nearby.

  • Missed dose? Take two the next day — levothyroxine is long-acting.

  • Birth-control pills can bind thyroid hormone → recheck labs after 4–6 weeks.

  • Tirosint (liquid capsule) helps if you have celiac, gastritis, or take acid reducers.

8. Evidence-Based Supplement Support

  • Selenium (80 µg daily) — lowers antibodies, supports gland health

  • Myo-inositol + selenium — improves TSH balance and well-being

  • Vitamin D — modulates immune activity

  • Nigella sativa (black cumin seed) — can help normalize TSH and weight

  • Ashwagandha — sometimes supports mild hypothyroid symptoms

  • Iron (+ vitamin C) — low ferritin (< 50 µg/L) worsens fatigue

⚠️ Avoid “thyroid support” blends or excess iodine — they can backfire on autoimmune thyroid disease.

9. T3 Add-On Therapy

For some people who stay symptomatic even with normal labs on T4:

  • Adding T3 (liothyronine) can help if the body struggles to convert T4 → T3.

  • Not for use in pregnancy or in those with heart rhythm disorders.

  • Should be a carefully supervised trial, never a DIY experiment.

10. Consequences of Ignoring It

Untreated or undertreated hypothyroidism can lead to:

  • Elevated cholesterol and cardiovascular disease

  • Fatty liver and metabolic slowdown

  • Insulin resistance or poor glucose control

  • Infertility, miscarriage risk, and irregular cycles

  • Depression, brain fog, low libido

  • Hair thinning, brittle nails, and skin changes

  • Cognitive decline and memory problems over time

💡 Bottom Line

“Normal” numbers can still hide a sluggish thyroid. The best clinicians look at the whole person—symptoms, labs, and response to treatment—to find balance. Don’t settle for being told “you’re fine” when your body says otherwise. The goal isn’t just to normalize TSH—it’s to feel well, think clearly, and live fully.

Always consult your healthcare provider before making medical decisions. Read the full disclaimer.

Read More